The ORR was 70% in patients treated with remestemcel-L, with 30% having a complete response and 41% having a partial response. The Food and Drug Administration (FDA) has approved Ryoncil ® ...
The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...
TIANJIN, China, Jan. 25, 2026 /PRNewswire/ -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal ...
Mesoblast (ASX:MSB) founder and CEO Prof Silviu Itescu has a markedly more relaxed demeanor than in the past, when investors ...
The company states: “Mesoblast (MESO) announced the FDA approved Ryoncil, remestemcel-L, as the first mesenchymal stromal cell, MSC, therapy in the United States. RYONCIL is the only MSC therapy ...
Discover how a new method for measuring iron flux helps scientists to rapidly identify high-quality cells for use in ...
USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping ...
Realizing the benefits of regenerative medicine will require a structural shift toward earlier detection and therapeutic intervention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results